Effects of Renal and Hepatic Impairment on the Pharmacokinetics of Zilurgisertib
British Journal of Clinical Pharmacology · 2025
DOI: 10.1002/bcp.70372 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, 2025. Verfasst von Yan-Ou Yang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacology and Pharmacometrics, Incyte Corporation, Wilmington, Delaware, USA. Hauptthemen laut MEDLINE: Kidney Failure, Chronic, Protein Kinase Inhibitors, Renal Insufficiency, Liver Diseases. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Incyte Corporation.
Abstract (Originalsprache)
Aim
Small‐molecule activin receptor‐like kinase‐2 inhibitor zilurgisertib (INCB000928) is under investigation in a pivotal trial for the treatment of fibrodysplasia ossificans progressiva (FOP), an ultrarare genetic condition. This analysis assessed effects of renal and hepatic impairment on zilurgisertib pharmacokinetics.
Methods
Two open‐label, parallel‐group studies were conducted. Participants with renal or hepatic impairment were matched with healthy controls and received a single 200‐mg dose of zilurgisertib; those with end‐stage renal disease (ESRD) received doses before and after haemodialysis. Plasma concentrations were quantified via validated assay; pharmacokinetic parameters were derived from non‐compartmental analysis. Geometric mean ratios (GMRs) and 90% confidence intervals (CIs) for C max , AUC 0‐t and AUC 0‐∞ were compared by ANOVA.
Results
Compared with matched controls, GMRs (90% CIs) for C max and AUC 0‐∞ were as follows: mild renal impairment, 0.92 (0.64–1.34) and 0.98 (0.77–1.24); moderate, 1.22 (0.92–1.63) and 1.64 (1.28–2.10); severe, 1.00 (0.74–1.35) and 1.70 (1.33–2.16), respectively. Among participants with ESRD, values were the following: before haemodialysis, 1.17 (0.91–1.49) and 1.47 (1.15–1.88); after, 1.32 (1.00–1.75) and 1.68 (1.29–2.19), respectively. Among participants with hepatic impairment, values were as follows: moderate, 1.06 (0.80–1.42) and 1.13 (0.93–1.38); severe: 1.36 (1.05–1.76) and 1.25 (1.06–1.48), respectively.
Conclusions
Zilurgisertib exposure was unchanged with mild renal or moderate hepatic impairment, but increased by 30%–70% with moderate or more severe renal impairment and by 25% with severe hepatic impairment. These findings, alongside the therapeutic index, to be defined by the ongoing pivotal FOP trial (NCT05090891), will guide dosing in these populations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Pharmacology and Pharmacometrics, Incyte Corporation, Wilmington, Delaware, USA.
- Department of Bioanalysis, Incyte Corporation, Wilmington, Delaware, USA.
- Department of Early Development, Incyte Corporation, Wilmington, Delaware, USA.
ORCID-Profile: Yan-Ou Yang, Phillip Wang
Förderung
- Incyte Corporation
Zitieren
APA
Yang, Y. O., Fang, Y., Wang, P., Liu, X., Getsy, J., & Rockich, K. (2025). Effects of Renal and Hepatic Impairment on the Pharmacokinetics of Zilurgisertib. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70372
Vancouver
Yang YO, Fang Y, Wang P, Liu X, Getsy J, Rockich K. Effects of Renal and Hepatic Impairment on the Pharmacokinetics of Zilurgisertib. British Journal of Clinical Pharmacology. 2025. doi:10.1002/bcp.70372
BibTeX
@article{Yang2025,
author = {Yang, Yan-Ou and Fang, Yunlan and Wang, Phillip and Liu, Xiang and Getsy, Jay and Rockich, Kevin},
title = {Effects of Renal and Hepatic Impairment on the Pharmacokinetics of Zilurgisertib},
journal = {British Journal of Clinical Pharmacology},
year = {2025},
doi = {10.1002/bcp.70372}
}
EUVIMED